Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of iC9-GD2-CAR T-cells in Relapsed/Refractory CNS Tumors
NCT05298995Phase 1Recruiting
- Start
- Nov 2023
- Primary completion
- Nov 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of GD2-CART01 in central nervous system tumor, medulloblastoma, embryonal tumor and 3 more (3 arms). Primary endpoint: Safety and definition of the Maximum Tolerated Dose / Recommended Dose at 4 weeks. Started Nov 2023; status: recruiting.
02
Drugs
GD2-CART01
03
Conditions
central nervous system tumormedulloblastomaembryonal tumorhigh-grade glioma (HGG)diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT05298995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05298995.